Under a tenth of individuals that would benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it releases its inaugural advice on the drugs.
With over a billion people worldwide now obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a long-term condition that can be treated with holistic and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major obstacles to widespread availability to the jabs that can assist patients in reducing substantial body mass, explains the agency.
Skinny Jab Supply Crisis
Even in the present most favorable outlook, the production of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of those who need them, per the WHO.
The guideline urges nations and manufacturers to widen access, via strategies including voluntary licensing.
The intellectual property rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of nations in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs mimick a natural hormone to reduce digestion speed, reduce hunger and enhance the sense of being full so people reduce food intake.
Individuals commonly see weight reduction in the initial weeks of beginning the once-weekly jabs.
Studies indicates people may see weight return after a year of discontinuing the medication, because their typical hunger resume.
Being above a healthy weight raises your risk for contracting diseases, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects people in every country and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.
